Ana Laus to Lung Neoplasms
This is a "connection" page, showing publications Ana Laus has written about Lung Neoplasms.
Connection Strength
0.760
-
Laus AC, de Paula FE, de Lima MA, Carlos CD, Gomes INF, de Marchi P, Valente JKN, Pioltini ABM, Miziara JE, da Silva CM, Viana LS, Scapulatempo-Neto C, Reis RM. EGF+61 A>G polymorphism is not associated with lung cancer risk in the Brazilian population. Mol Biol Rep. 2019 Apr; 46(2):2417-2425.
Score: 0.383
-
Raquel-Cunha A, Pinheiro J, Marques RF, Font?o P, Cardoso-Carneiro D, Mendes A, Gomes INF, Laus AC, da Silva-Oliveira RJ, Reis RM, Martinho O. RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR-targeted therapies. Mol Oncol. 2025 Nov; 19(11):3205-3222.
Score: 0.150
-
da Silva-Oliveira RJ, Gomes INF, da Silva LS, Lengert AVH, Laus AC, Melendez ME, Munari CC, Cury FP, Longato GB, Reis RM. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines. Int J Mol Sci. 2022 Jul 14; 23(14).
Score: 0.121
-
Leal LF, Laus AC, Cavagna R, de Paula FE, de Oliveira MA, Ribeiro DM, Hassan FM, Miziara JE, da Silva ECA, da Silva VD, De Marchi P, Reis RM. EGF+61 A>G polymorphism does not predict response to first-generation EGFR tyrosine kinase inhibitors in lung cancer patients. Thorac Cancer. 2020 10; 11(10):2987-2992.
Score: 0.107